📰 Practice Guidelines News
Page 9 - Practice Guidelines News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Practice Guidelines. Real-time updates on events, politics, business and more.
January 9, 2024
The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.
January 8, 2024
– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial...
January 5, 2024
Medical oncologist Lucio N. Gordan MD, president and managing physician of Florida Cancer Specialists & Research Institute, LLC, is lead author of the first real-world study comparing the two preferred regimens recommended for the primary treatment of non-transplant patients with newly-diagnosed multiple myeloma, published recently in Science Direct.
January 4, 2024
LONGUEUIL, Quebec, Jan. 04, 2024 -- Azimut Exploration Inc. is pleased to announce that it has filed on SEDAR+ an independent Technical Report prepared in accordance with National Instrument...
January 4, 2024
Azimut Exploration Inc. ("Azimut" or the "Company") is pleased to announce that it has filed on SEDAR+ an independent Technical Report (the "Report") prepared in accordance with National Instrument 43-101 for the Patwon Gold Zone on its 100% owned...
January 4, 2024
U.S. EMBASSY OUAGADOUGOU VACANCY ANNOUNCEMENT # Ouaga-2023-033 RA1 REGISTERED NURSE Opening Date : January 05, 2024 Closing Date : January (...)
January 4, 2024
Azimut Exploration Inc. is pleased to announce that it has filed on SEDAR+ an independent Technical Report prepared in accordance with National Instrument 43-101 for the Patwon Gold Zone on its 100% owned Elmer Property in the Eeyou Istchee James Bay... - Veroeffentlicht am 04.01.2024
January 1, 2024
New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program
December 28, 2023
SHANGHAI, Dec. 28, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announces that recently, PT Kalbio Global Medika, the subsidiary of Henlius'
December 20, 2023
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading academic cancer centers in the United States—is celebrating six years...